Therapeutic Effects of Nandrolone and Testosterone in Adult Male HIV Patients With AIDS Wasting Syndrome (AWS): A Randomized, Double-Blind, Placebo-Controlled Trial

REFERENCES

• Siddiqui J, Phillips AL, Freedland ES, Sklar AR, Darkow T, Harley CR. Prevalence and cost of HIV-associated weight loss in a managed care population. Curr Med Res Opin. 2009;25(5):1307–1317.
   PubMed Web of Science ®Google Scholar
• Mangili A, Murman DH, Zampini AM, Wanke CA. Nutri-tion and HIV infection: review of weight loss and wast-ing in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. Clin Infect Dis. 2006;42(6):836–842.
   PubMed Web of Science ®Google Scholar
• Tang AM, Forrester J, Spiegelman D, Knox TA, Tchetgen E, Gorbach SL. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:230–236.
   PubMed Web of Science ®Google Scholar
• Shikuma CM, Zackin R, Settler F, Mildvan D, Nyangweso P, Alston B, Evans S, Mulligan K; AIDS Clinical Trial Group 892 Team. Changes in weight and lean body mass dur-ing highly active antiretroviral therapy. Clin Infect Dis. 2004;39(8)1223–1230.
   Web of Science ®Google Scholar
• Strawford A, Hellerstein M. The etiology of wasting in the human immunodeficiency virus and acquired immunodefi-ciency syndrome. Semin Oncol. 1998;25:76–81.
   PubMed Web of Science ®Google Scholar
• Corcoran C, Grinspoon S. Treatments for wasting in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1999;340:1740–1750.
   PubMed Web of Science ®Google Scholar
• Nemechek PM, Polsky B, Gottlieb MS. Treatment guidelines for HIV-associated wasting. Mayo Clin Proc. 2000;75:386–394.
   PubMed Web of Science ®Google Scholar
• Ottery FD, Walsh D, Strawford A. Pharmacologic management of anorexia/cachexia. Semin Oncol. 1998;25:35–44.
   PubMed Web of Science ®Google Scholar
• Oster MH, Enders SR, Samuels SJ, et al. Megestrol ace-tate in patients with AIDS and cachexia. Ann Intern Med. 1994;121:400–408.
   PubMed Web of Science ®Google Scholar
• Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med. 1994;121(6):393–399.
   PubMed Web of Science ®Google Scholar
• Hoh R, Pelfini A, Neese RA, et al. De novo lipogenesis predicts short-term body-composition response by bioelec-tricel impedance analysis to oral nutritional supplements in HIV-associated wasting. Am J Clin Nutr 1998;68(1): 154–163.
   PubMed Web of Science ®Google Scholar
• Silva M, Skolnik PR, Gorbach SL, et al. The effect of pro-tease inhibitors on weight and body composition in HIV-infected patients. AIDS. 1998;12(13):1645–1651.
   PubMed Web of Science ®Google Scholar
• Schwenk A, Beisenherz A, Kremer G, Diehl V, Salzberger B, Fatkenheuer G. Bioelectrical impedance analysis in HIV-infected patients treated with triple antiretroviral treatment. Am J Clin Nutr 1999;70:867–873.
   PubMed Web of Science ®Google Scholar
• Berger D, Cimoch P, Nemechek P, Meyer KL. Measure-ment of body cell mass in patients receiving highly active antiretroviral therapy (HAART). In: Program and abstracts of the 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; September to October 1997; Toronto, Ontario.
   Google Scholar
• Zueman D, Teixeira A, Olivieri M, Marks M. Correlation between body composition, caloric intake and plasma viral load in HIV infected patients. Nutrition. 1997;13:293A.
   Google Scholar
• Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med. 1996;125(11):873–882.
   PubMed Web of Science ®Google Scholar
• Strawford A, Barbieri T, Neese R, et al. Effects of nan-drolone decanoate therapy in borderline hypogonadal men with HIV associated weight loss. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20(2):137–146.
   PubMedGoogle Scholar
• Forbes GB. The effect of anabolic steroids on lean body mass: the dose response curve. Metabolism. 1985,34:571–573.
   PubMed Web of Science ®Google Scholar
• Forbes GB, Porta CR, Herr BE, Griggs R. Sequence of changes in body composition induced by testosterone and reversal of changes after drug is stopped. JAMA. 1992;267:397–399.
   PubMed Web of Science ®Google Scholar
• Harris JA, Benedict FG. A Biometric Study of Basal Metabolism in Man. Washington, DC: Carnegie Institute of Washington; 1919.
   Google Scholar
• Mulligan K, Zackin R, Clark RA, et al. Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. 2005:578–585.
   PubMed Web of Science ®Google Scholar
• Saha B, Rajadhyaksha GC, Ray SK. Beneficial effects of nandrolone decanoate in wasting associated with HIV. J Indian Med Assoc. 2009;107(5):295–299.
   PubMedGoogle Scholar
• Gold J, Batterham MJ, Rekers H, et al. Effects of nan-drolone decanoate compared with placebo or testosterone on HIV-associated wasting. HIV Med. 2006;7(3): 146–155.
   PubMed Web of Science ®Google Scholar
• Kelkar D, Deshpande AK. Hypogonadism & HIV wasting: an Indian scenario. Presented at: International Conference on AIDS; July 7–12, 2002. Abstract B10335.
   Google Scholar
• Singh RB, Niaz MA, Beegom R, Wander GS, Thakur AS, Rissam HS. Body fat percent by bioelectrical impedance analysis and risk of coronary artery disease among urban men with low rates of obesity: the Indian paradox. J Am Coll Nutr 1999;18(3):268–273.
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Corcoran C, Askari H, et al. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-con-trolled trial. Ann Intern Med. 1998:18–26.
   PubMed Web of Science ®Google Scholar
• Coodley GO, Coodley MK. A trial of testosterone therapy for HIV-associated weight loss AIDS. 1997;11:1347–1352.
   PubMed Web of Science ®Google Scholar
• Storer TW, Woodhouse LJ, Settler F, Singh AB. A random-ized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment J Clin Endocrinol Metab. 2005;90:4474-4482.
   Google Scholar
• Grinspoon S, Corcoran C, Lee K, et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab. 1996;81(11):4051–4058.
   PubMed Web of Science ®Google Scholar
• Merenich JA, McDermott MT, Asp AA, Harrison SM, Kidd GS. Evidence of endocrine involvement early in the course of human immunodeficiency virus infection. J Clin Endo-crinol Metab. 1990;70:566–571.
   PubMed Web of Science ®Google Scholar
• Raffi F, Brisseau JM, Planchon B, Remi JP, Barrier JH, Grolleau JY. Endocrine function in 98 HIV-infected patients: a prospective study. AIDS. 1991;5:729–733.
   PubMed Web of Science ®Google Scholar
• Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med. 1988;84:611–616.
   PubMed Web of Science ®Google Scholar
• Wachtel T, Piette J, Mor V, Stein M, Fleishman J, Car-penter C. Quality of life in persons with human immu-nodeficiency virus infection: measurement by the Medical Outcomes Study instrument. Ann Intern Med. 1992;116:129–137.
   PubMed Web of Science ®Google Scholar